Concepedia

Author

Preetesh Jain

The University of Texas MD Anderson Cancer CenterORCID

Also Known As

P Jain, P. Jain, Preetesh Jain, S Godbole

466

Publications

7.6K

Citations

47

H-Index

81

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterTel Aviv UniversityUniversity of California, IrvineRabin Medical CenterThe University of Texas Health Science Center at Houston
PJ

About

Preetesh Jain is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

22

36

2K

2

Health Sciences

11

12

582

3

Natural Sciences

1

1

13

4

Biochemistry

1

1

13

5

Biostatistics

1

1

34

Preetesh Jain

×

96

Publications

5.7K

Citations

41

H-Index

YearCitations

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

Preetesh Jain, Michael J. Keating, William G. Wierda,

Blood

2015

333

Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials

Koji Sasaki, Sara S. Strom, Susan O’Brien,

The Lancet Haematology

2015

303

<i>TP53</i> mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes

Tapan M. Kadia, Preetesh Jain, Farhad Ravandi,

Cancer

2016

262

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Christoph K. Stein‐Thoeringer, Neeraj Saini, Eli Zamir,

Nature Medicine

2023

206

Chronic Lymphocytic Leukemia

Preetesh Jain, R. Kanti

Emerging Cancer Therapeutics

2011

203

Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients

Preetesh Jain, Hagop M. Kantarjian, Ahmad Ghorab,

Cancer

2017

160

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

Yucai Wang, Preetesh Jain, Frederick L. Locke,

Journal of Clinical Oncology

2023

155

Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors

Preetesh Jain, Hagop M. Kantarjian, Keyur P. Patel,

Blood

2016

150

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Ohad Benjamini, Preetesh Jain, Long Trinh,

Leukemia & lymphoma/Leukemia and lymphoma

2014

149

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

Preetesh Jain, Hagop M. Kantarjian, Aziz Nazha,

Blood

2013

134

Page 1